Vanquish receives FDA clearance for circumferential reduction

BTL has announced the FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area.

The system’s patented technology creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue.

“BTL Vanquish is truly a breakthrough technology. Published clinical studies show it permanently destroys unwanted fat for safe and measurable circumferential reduction of the abdominal area without the cost and inconvenience of surgery,” says David McDaniel, MD, a leading dermatologist and investigator of high-tech devices for non-invasive body contouring. “FDA clearance of Vanquish is a significant step forward in providing the newest treatment option for body slimming and shaping.”

“FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference,” said Andrea Morrison, BTL’s Director of Clinical Development. “BTL is proud to offer patients a comfortable, affordable and noninvasive body shaping experience. This regulatory milestone underscores BTL’s commitment to deliver meaningful solutions to aesthetic patient care.”